- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06667908
En studie av JNJ-90301900 i kombination med kemoradiation följt av konsoliderande immunterapi för icke-småcellig lungcancer (NSCLC) (CONVERGE)
En fas 2, randomiserad, öppen, aktivt kontrollerad studie av JNJ-90301900 i kombination med kemoradiation följt av Durvalumab i lokalt avancerad och icke-operbar steg III NSCLC
The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Study Contact
- Telefonnummer: 844-434-4210
- E-post: Participate-In-This-Study1@its.jnj.com
Studieorter
-
-
-
Camperdown, Australien, 2050
- Rekrytering
- Chris O'Brien Lifehouse
-
Herston, Australien, 4029
- Rekrytering
- Royal Brisbane and Women's Hospital
-
Nedlands, Australien, 6009
- Rekrytering
- Sir Charles Gairdner Hospital
-
North Ryde, Australien, 2109
- Rekrytering
- Macquarie University
-
Parkville, Australien, 3050
- Rekrytering
- Royal Melbourne Hospital
-
-
-
-
-
Barretos, Brasilien, 14784 400
- Rekrytering
- Fundacao Pio XII
-
São Paulo, Brasilien, 05651 901
- Rekrytering
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo, Brasilien, 01308 050
- Rekrytering
- Sociedade Beneficente de Senhoras Hospital Sirio Libanes
-
-
-
-
-
Brest, Frankrike, 29200
- Rekrytering
- Hopital De La Cavale Blanche
-
Marseille, Frankrike, 13015
- Rekrytering
- Hopital Nord Marseille
-
Paris, Frankrike, 75248
- Rekrytering
- Institut Curie
-
Paris, Frankrike, 75020
- Rekrytering
- Hopital Tenon
-
Rouen, Frankrike, 76000
- Rekrytering
- CHU Rouen Hopital Charles Nicolle
-
Villejuif, Frankrike, 94805
- Rekrytering
- Gustave Roussy
-
-
-
-
California
-
La Jolla, California, Förenta staterna, 92037
- Rekrytering
- Moores Cancer Center at UC San Diego Health
-
-
Connecticut
-
Farmington, Connecticut, Förenta staterna, 06030
- Avslutad
- University of Connecticut Health Center
-
New Haven, Connecticut, Förenta staterna, 06519
- Rekrytering
- Yale University
-
-
Florida
-
Miami, Florida, Förenta staterna, 33136
- Rekrytering
- University of Miami
-
Orlando, Florida, Förenta staterna, 32806
- Rekrytering
- Orlando Health Cancer Institute
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30306
- Rekrytering
- Emory University Winship Cancer Institute
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02215
- Rekrytering
- Beth Israel Deaconess Medical Center
-
-
Missouri
-
St Louis, Missouri, Förenta staterna, 63130
- Rekrytering
- Washington University in St Louis
-
-
New Jersey
-
New Brunswick, New Jersey, Förenta staterna, 08901
- Rekrytering
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
New York, New York, Förenta staterna, 10016
- Rekrytering
- NYU Langone Health
-
New York, New York, Förenta staterna, 10065
- Rekrytering
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Förenta staterna, 27514
- Rekrytering
- University of North Carolina at Chapel Hill
-
Pinehurst, North Carolina, Förenta staterna, 28374
- Rekrytering
- FirstHealth of the Carolinas
-
-
Ohio
-
Cleveland, Ohio, Förenta staterna, 44106
- Rekrytering
- University Hospitals Cleveland Medical Center
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97239
- Rekrytering
- Oregon Health And Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- Rekrytering
- University of Pennsylvania
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- Rekrytering
- MD Anderson Cancer Center
-
-
Vermont
-
Burlington, Vermont, Förenta staterna, 05401
- Rekrytering
- University of Vermont Medical Center
-
-
-
-
-
Shatin, Hong Kong
- Rekrytering
- Prince of Wales Hospital
-
-
-
-
-
Dongguan, Kina, 523109
- Rekrytering
- Dongguan People s Hospital
-
Guangzhou, Kina, 510080
- Rekrytering
- The First Affiliated Hospital Sun Yat sen University
-
Jinan, Kina, 250117
- Rekrytering
- The Affiliated Cancer Hospital of Shandong First Medical University
-
-
-
-
-
Amsterdam, Nederländerna, 1066 CX
- Rekrytering
- Antoni van Leeuwenhoek
-
Nijmegen, Nederländerna, 6525 GA
- Rekrytering
- Radboud Umcn
-
-
-
-
-
Madrid, Spanien, 28041
- Rekrytering
- Hosp. Univ. 12 de Octubre
-
Pamplona, Spanien, 31008
- Rekrytering
- Clinica Univ. de Navarra
-
Santiago de Compostela, Spanien, 15706
- Rekrytering
- Hosp. Clinico Univ. de Santiago
-
Valencia, Spanien, 46026
- Rekrytering
- Hosp. Univ. I Politecni La Fe
-
-
-
-
-
London, Storbritannien, NW1 2BU
- Rekrytering
- University College London Hospitals
-
-
-
-
-
Istanbul, Turkiet (Türkiye), 34899
- Rekrytering
- Marmara University Pendik Training Hospital
-
Sakarya, Turkiet (Türkiye), 54100
- Rekrytering
- Sakarya University Training and Research Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Must be a candidate for standard of care (SOC) treatment of non small cell lung cancer (NSCLC) by concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation durvalumab treatment as determined by the investigator and per local guidelines at screening
- Have a medical history of pathologically (histologically or cytologically) proven diagnosis of NSCLC within 3 months prior to enrollment/randomization
- Have locally advanced unresectable stage III NSCLC according to the eighth edition lung cancer stage classification
- Have at least 1 target lesion (primary lung lesion or involved lymph node[s]) per RECIST version 1.1 that is amenable to intratumoral and/or intranodal injection and intensity modulated radiation therapy (IMRT) as determined by the investigator at screening
- Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1
Exclusion Criteria:
- Medical history of: (a) Primary immunodeficiency (b) Organ transplant that requires therapeutic immunosuppression
- Any of the following within 3 months prior to enrollment/randomization: severe or unstable angina, myocardial infarction, clinically significant ventricular arrhythmias or heart failure New York heart association functional classification class III to IV
- Another concurrent or prior primary malignancy within the last 36 months at informed consent
- Known allergies, hypersensitivity, or intolerance to any ingredients of JNJ-90301900 crystalline solution, platinum-based doublet chemotherapy (ChT), or durvalumab
- History of coagulation disorders, including: (a) Active bleeding diathesis or requirement for therapeutic anticoagulation or antiplatelet that cannot be interrupted or altered for JNJ-90301900 injection procedures, (b) Major thromboembolic events (for example, pulmonary embolism, cerebrovascular accident) within 3 months of enrollment or randomization
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Part 1: Cohort A and Cohort B
Participants will receive JNJ-90301900 injected intratumorally and/or intranodally (cohort A: 22% gross tumor volume [GTV] and cohort B: 33% GTV) along with cCRT (concurrent chemotherapy with radiation therapy) followed by consolidation immunotherapy (cIT) to evaluate feasibility of JNJ-90301900 injection procedure. |
JNJ-90301900 will be injected intratumorally and/or intranodally. Durvalumab will be administered as intravenous (IV) infusion as cIT. Radiation by intensity modulated radiation therapy (IMRT) will be administered. Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy. Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy. |
|
Experimentell: Part 2: Arm A and Arm B
Participants will receive JNJ-90301900 injected intratumorally and/or intranodally (Arm A: 22% GTV and Arm B: 33% GTV) along with cCRT followed by cIT to evaluate the efficacy and safety of JNJ-90301900. |
JNJ-90301900 will be injected intratumorally and/or intranodally. Durvalumab will be administered as intravenous (IV) infusion as cIT. Radiation by intensity modulated radiation therapy (IMRT) will be administered. Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy. Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy. |
|
Aktiv komparator: Part 2: Arm C: (Control treatment)
Participants will receive treatment with cCRT followed by cIT as control treatment to evaluate the efficacy and safety of JNJ-90301900. |
Durvalumab will be administered as intravenous (IV) infusion as cIT. Radiation by intensity modulated radiation therapy (IMRT) will be administered. Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy. Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Objective Response Rate (ORR) Using Independent Central Review (ICR) Assessment
Tidsram: Up to 2 Years and 2 months
|
ORR is defined as the percentage of participants who have a best response of complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST) version (v) 1.1 using ICR assessments. |
Up to 2 Years and 2 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Objective Response Rate (ORR) Post-cCRT and Pre-cIT
Tidsram: Up to 12 Weeks
|
Objective response rate is defined as percentage of participants who achieve CR or PR, post-concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) and pre-consolidation immunotherapy (cIT) based on investigator's assessment according to RECIST v1.1. |
Up to 12 Weeks
|
|
Disease Control Rate (DCR) Post-cCRT and Pre-cIT
Tidsram: Up to 12 Weeks
|
DCR is defined as percentage of participants who achieve CR, PR and stable disease post-cCRT and pre-cIT based on investigator's assessment according to RECIST v1.1. |
Up to 12 Weeks
|
|
Objective Response Rate (ORR) as Assessed by the Investigator
Tidsram: Up to 2 Years and 2 months
|
ORR is defined as the percentage of participants who have a best response of CR or PR using RECIST v1.1 as assessed by the investigator. |
Up to 2 Years and 2 months
|
|
Progression Free Survival (PFS)
Tidsram: Up to 2 Years and 2 months
|
PFS is defined as the time from the enrollment/randomization until disease progression or death due to any cause according to RECIST v1.1. |
Up to 2 Years and 2 months
|
|
Duration of Response (DoR)
Tidsram: Up to 2 Years and 2 months
|
DoR will be calculated among responders from the date of initial documentation of a response to the date of first documented evidence of relapse according to RECIST v1.1, or death due to any cause, whichever occurs first. |
Up to 2 Years and 2 months
|
|
Time to Locoregional Failure (LRF)
Tidsram: Up to 2 Years and 2 months
|
Time to LRF is defined as the time from enrollment/randomization to the first LRF using ICR assessments. |
Up to 2 Years and 2 months
|
|
Time to Distant Failure (DF)
Tidsram: Up to 2 Years and 2 months
|
Time to DF is defined as the time from enrollment/randomization to the first DF using ICR assessments. |
Up to 2 Years and 2 months
|
|
Number of Participants with Treatment-Emergent Adverse Event (TEAE) Related to Study Treatment
Tidsram: Up to 2 Years and 2 months
|
TEAE is defined as any new or worsening adverse event (AE) occurring at or after the initial administration of study treatment through the day of last dose of study treatment received plus 30 days or prior to the start of subsequent anticancer therapy (non-durvalumab), whichever is earlier, or any follow-up AE with onset date and time beyond 30 days after the last dose of study treatment but prior to the start of subsequent anticancer therapy, or any AE that is considered treatment-related regardless of the start date of the event. TEAEs related to JNJ-90301900 injection procedure, JNJ-90301900, RT, ChT, or cIT will be reported. |
Up to 2 Years and 2 months
|
|
Number of Participants Reporting Laboratory Parameters, Physical Examination, Vital Signs Including Eastern Cooperative Oncology Group (ECOG) Performance Status Abnormalities
Tidsram: Up to 2 Years and 2 months
|
Participants with laboratory parameters, physical examination, vital signs including ECOG performance status abnormalities will be reported. |
Up to 2 Years and 2 months
|
Samarbetspartners och utredare
Utredare
- Studierektor: Johnson & Johnson Enterprise Innovation Inc. Clinical Trial, Johnson & Johnson Enterprise Innovation Inc.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 90301900NSC2001
- 90301900NSC2001 (Annan identifierare: Janssen Research & Development, LLC)
- 2024-518276-32-00 (Registeridentifierare: EUCT number)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .